Platform Expansion Succeeds

OpenAI completes the Orchestra Bio acquisition and positions it as the foundation for a regulated life-sciences platform. The most likely path is a measured expansion into clinical decision support, drug discovery tooling, and partnerships with hospitals or pharma companies rather than immediate end-to-end drug development.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.